Iovance Biotherapeutics, Inc.
IOVA
Xếp hạng trong cổ phiếu
#2862
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Giá cổ phiếu
$14.12
Vốn hóa thị trường
$6.40B
Thay đổi (1 ngày)
-3.42%
Thay đổi (1 năm)
556.74%
Quốc gia
US
Giao dịch Iovance Biotherapeutics, Inc. (IOVA)
Danh mục
Healthcare
Lịch sử giá cổ phiếu của Iovance Biotherapeutics, Inc. (IOVA)
Giá đóng cửa cao nhất: $14.11 vào 2026-10-01
Giá đóng cửa thấp nhất: $103.55 vào 2010-10-01
Giá đóng cửa thấp nhất: $103.55 vào 2010-10-01
Lịch sử giá cổ phiếu của Iovance Biotherapeutics, Inc. từ 2010 đến 2026
Hiệu suất giá cổ phiếu hàng năm
| Năm | Hiệu suất |
|---|---|
| 2026 (TTM) | 100.19% |
| 2025 | -69.46% |
| 2024 | 9.49% |
| 2023 | 11.39% |
| 2022 | -64.95% |
| 2021 | -60.13% |
| 2020 | 75.74% |
| 2019 | 190.57% |
| 2018 | 7.35% |
| 2017 | 24.29% |
| 2016 | -11.09% |
| 2015 | 11.54% |
| 2014 | -28.26% |
| 2013 | -59.07% |
| 2012 | -76.79% |
| 2011 | -13.84% |
| 2010 | 0.00% |
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
| Công ty | Giá cổ phiếu | Thay đổi 1năm% | Quốc gia |
|---|---|---|---|
| $536.87 | 25.89% |
US
|
|
| $191.60 | 613.60% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $884.30 | 8.61% |
NL
|
